NRx Pharmaceuticals (NASDAQ:NRXP) Given New $49.00 Price Target at Ascendiant Capital Markets

NRx Pharmaceuticals (NASDAQ:NRXP) had its target price raised by Ascendiant Capital Markets from $48.00 to $49.00 in a report issued on Monday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

Other analysts also recently issued reports about the stock. D. Boral Capital reissued a “buy” rating and issued a $34.00 price target on shares of NRx Pharmaceuticals in a report on Monday, April 20th. HC Wainwright reissued a “buy” rating and issued a $45.00 price target on shares of NRx Pharmaceuticals in a report on Monday. BTIG Research reissued a “buy” rating and issued a $25.00 price target on shares of NRx Pharmaceuticals in a report on Tuesday, March 24th. Zacks Research raised shares of NRx Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Monday, March 2nd. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of NRx Pharmaceuticals in a report on Monday, December 29th. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $38.25.

NRx Pharmaceuticals Price Performance

Shares of NRx Pharmaceuticals stock opened at $3.03 on Monday. NRx Pharmaceuticals has a fifty-two week low of $1.62 and a fifty-two week high of $3.84. The firm has a fifty day moving average price of $2.15 and a two-hundred day moving average price of $2.33. The company has a market cap of $100.20 million, a PE ratio of -2.18 and a beta of 1.83.

NRx Pharmaceuticals (NASDAQ:NRXP) last issued its quarterly earnings results on Monday, March 23rd. The company reported $0.19 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.28. The company had revenue of $0.98 million during the quarter, compared to the consensus estimate of $7.53 million. Analysts expect that NRx Pharmaceuticals will post 0.13 earnings per share for the current fiscal year.

Hedge Funds Weigh In On NRx Pharmaceuticals

A number of hedge funds have recently made changes to their positions in NRXP. Anson Funds Management LP raised its stake in shares of NRx Pharmaceuticals by 50.3% in the 4th quarter. Anson Funds Management LP now owns 3,043,957 shares of the company’s stock valued at $8,249,000 after buying an additional 1,018,853 shares in the last quarter. Commonwealth Equity Services LLC acquired a new position in shares of NRx Pharmaceuticals in the 4th quarter valued at $994,000. Bleakley Financial Group LLC acquired a new position in shares of NRx Pharmaceuticals in the 4th quarter valued at $318,000. Vanguard Group Inc. raised its stake in shares of NRx Pharmaceuticals by 18.3% in the 3rd quarter. Vanguard Group Inc. now owns 534,956 shares of the company’s stock valued at $1,765,000 after buying an additional 82,781 shares in the last quarter. Finally, AdvisorShares Investments LLC raised its stake in shares of NRx Pharmaceuticals by 29.7% in the 3rd quarter. AdvisorShares Investments LLC now owns 342,136 shares of the company’s stock valued at $1,129,000 after buying an additional 78,339 shares in the last quarter. Institutional investors and hedge funds own 4.27% of the company’s stock.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.